/Investor DB

xista science ventures — 2026 Investments

4 investments dated 2026 · listed companies and verified rows first · show all

AVES Realityavesreality.cominJan 2026

AVES Reality converts real-world geographic data into simulation-ready 3D digital environments and HD maps for industrial applications.

AI & Machine LearningDeep TechDeveloper ToolsSaaSGarmisch-Partenkirchen, DE

Florian Albert(Co-founder)inSeverin Knebel(Co-founder)inMatthias Heger(Co-founder)in

Co-investorsBayern KapitalFraunhofer Tech Transfer FundMatterwave Ventures

Collimate Healthcollimatehealth.cominJun 2026 · $6.9M

CollimateHealth develops a clinically scalable microbeam radiation technology for cancer treatment, delivering arrays of narrow, micrometer-scale radiation beams at higher doses than conventional broad-beam radiation oncology.

BiotechHealthtechMedical Devices

Stefan Bartzsch(Co-founder & Chief Scientific Officer)inJohanna Winter(Co-founder & Chief Technology Officer)inHans Maria Heÿn(Co-founder & Chief Executive Officer)in

Co-investorsPositron VenturesCaesar VenturesHTGF

Constructorconstructor.comin𝕏Jun 2026

Constructor provides AI-powered product search and discovery software for ecommerce retailers.

AI & Machine LearningE-commerceRetail TechSaaSSan Francisco, US

Eli Finkelshteyn(Founder)inDan McCormick(Founder, former CTO at Shutterstock)inIgor Finkelshteyn(Executive Officer, Director)

BoardAsh Fontana(Director)in

Co-investorsFusionHemisphere Ventures LLCSapphire VenturesSignia Venture PartnersSilversmith Capital PartnersGreencode Ventures+1 more

VALANXvalanx.bioin𝕏Mar 2026

VALANX Biotech develops a site-specific protein conjugation technology (GoldenSite) using click-chemistry to produce homogeneous antibody-drug conjugates with optimized conjugation sites.

AI & Machine LearningBiotech

Michael Lukesch(CEO & Founder)inGeorg Altenbacher(CBO & Co-Founder)inKlaus Orlinger(Chief Scientific Officer)in

Co-investorsSOSV

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.